



OxPLoreD

Spring 2025



THANK YOU!

Thank you for your continued interest in OxPLoreD, a study involving people with early-stage lymphoproliferative disorders. The study aims to further confirm already known clinical characteristics that predict whether people diagnosed with precursor leukaemia or a very early stage of blood cancer might go on to developing full-blown cancer that needs treatment. As a second aim, OxPLoreD also tries to identify additional genetic markers in the B-lymphoid cells and more generally in the immune-system that might make this prediction more precise.

At the end of 2023 we finished enrolling new participants on OxPLoreD. Just under 600 people have contributed.

Thank you to each of you who have participated and continue to participate in OxPLoreD. Read on to find out what's next for this vital study.

THE AIMS OF OxPLoreD

- To prospectively validate the clinical International Prognostic Score for Early CLL (IPS-E)
- To identify and validate additional genomic and immunological predictive markers of progression to malignant disease
- To assess Quality of Life of patients with pre-cancerous lymphoid conditions
- To study other clinical complications associated with pre-malignancy (infection, bony fractures, thrombosis and deaths not to progression to lymphoid cancers)
- To establish evidence-based guidance for monitoring and follow-up of patients with pre-cancerous conditions

END OF STUDY

If you joined the study at the end of 2020 or later you may have received a letter from your hospital recently, telling you about changes to your follow-up. To summarise:

The OxPLoreD study reaches its conclusion later in 2025.

Instead of seeing you at 5 years, we would like to see you at 3 years to complete your final clinical assessments at the study clinic.

Between July and September 2025, we would like to have a telephone follow up with you to see how you have been getting on, and to find out about any treatments you may have had for your condition. We will not need to see you if your visit is due after September 2025, but we would still like to carry out the telephone follow-up.

Please contact your hospital if you would like further details. Contact information is available at <https://explored.oncology.ox.ac.uk/patient-information-resources-1>

WHAT'S NEXT?

The study closed to recruitment early as the number of people with precursor CLL progressing to needing treatment was sufficient to confirm the clinical IPS-E.

Interim results on the genetic and immune system results in CLL were shown as posters at 2 international conferences in 2023, in San Diego and Boston, USA. Both posters demonstrated progress toward predicting which groups of people might benefit from earlier treatment, but the final clinical follow-up results in December 2025 are needed before we can finalise the analysis. The abstract from one of posters is available at <https://ash.confex.com/ash/2023/webprogram/Paper185268.html>

In the coming year, we will be preparing four main scientific papers. The first paper will describe symptoms and quality of life of people with very early stage MBL/CLL. The second paper will focus on the IPS-E validation. The third paper will summarise the early genetic changes we see in the pre-cancer cells. The Fourth will focus on changes in the immune cells. All this information will be used to predict the probability of people with MBL/CLL progressing in future to needing treatment. For MGUS/Myeloma we are planning to follow a similar approach.

Thank you for taking the time to read this newsletter, which we hope you have found informative. We look forward to sharing results with you as they become available. If you have any queries about your care, please talk to the study team at your hospital.

For more general information about this study, please visit <https://explored.oncology.ox.ac.uk/> or scan the QR code opposite. Future updates will be available in the "Publications" section.



OXFORD
CENTRE

